(November 6 – 12, 2020)

* * * *

CMS Makes Announcement Regarding Coverage of COVID-19 Antibody Treatment

The Centers for Medicare & Medicaid Services (“CMS”) have issued an announcement regarding Medicare coverage of monoclonal antibody treatments for COVID-19.  This follows the FDA’s issuance of an Emergency Use Authorization (on November 9, 2020) for the use of bamlanivimab in treating mild-to-moderate COVID-19.  People with Medicare will not be required to make cost sharing payments (e.g., coinsurance, copayments, and deductibles) for this treatment.  More information is available here.

CMS Publishes Interim Final Rule

CMS has published an interim final rule in the Federal Register discussing the agency’s implementation of certain provisions of the CARES Act.  Among other things, this addresses price transparency for COVID-19 diagnostic tests, add-on payments for cases involving the use of new COVID-19 treatments, and updates for the Comprehensive Care for Joint Replacement (“CJR”) model.  The interim final rule is available here.

Back to Top of Page